32 completed. 32 Phase 3.
By phase and status
Follow IVA: new trials by email Literature Review of IVA trials Research Report on IVA
Trials (filtered) newest first · largest first
All 32 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 67 | 2023-06-27 | 2026-10-15 |
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
ELX/TEZ/IVA, IVA, Placebo (matched to ELX/TEZ/IVA) - Cystic Fibrosis | Phase 3 | Completed | 307 | 2022-05-09 | 2024-08-01 |
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 71 | 2022-01-17 | 2026-03-03 |
A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 86 | 2022-01-14 | 2023-07-11 |
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 597 | 2021-10-27 | 2024-06-13 |
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 82 | 2021-10-12 | 2025-09-24 |
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 435 | 2021-09-14 | 2024-10-03 |
A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 69 | 2021-01-15 | 2023-08-03 |
A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 120 | 2021-01-11 | 2024-05-08 |
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 83 | 2020-11-19 | 2023-06-28 |
A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes
ELX/TEZ/IVA, IVA, Placebo (matched to ELX/TEZ/IVA) - Cystic Fibrosis | Phase 3 | Completed | 121 | 2020-06-19 | 2022-07-26 |
A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 172 | 2020-05-04 | 2023-07-28 |
Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 64 | 2020-02-17 | 2025-05-18 |
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 251 | 2019-12-05 | 2024-01-16 |
A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del
ELX/TEZ/IVA, TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 176 | 2019-10-03 | 2021-08-18 |
A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
ELX/TEZ/IVA, IVA, TEZ/IVA - Cystic Fibrosis | Phase 3 | Completed | 271 | 2019-08-28 | 2021-07-02 |
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 458 | 2019-08-09 | 2023-07-06 |
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 507 | 2018-10-09 | 2025-09-24 |
Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
ELX/TEZ/IVA, IVA - Cystic Fibrosis | Phase 3 | Completed | 71 | 2018-10-02 | 2021-10-22 |
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
LUM, IVA - Cystic Fibrosis | Phase 3 | Completed | 61 | 2018-09-07 | 2023-01-06 |
Showing 20 of 32. Sign in to see all of them.
Conditions studied
Cystic Fibrosis (32)
Sponsors
Vertex Pharmaceuticals Incorporated (32)
Countries
Australia (27) · Canada (24) · United Kingdom (24) · Germany (21) · United States (21) · Belgium (15) · Ireland (14) · Spain (14) · France (13) · Netherlands (12) · Denmark (11) · Israel (10) · Switzerland (10) · Italy (8) · Austria (6)
Results publications
PMID 37983082, PMID 33331662, PMID 39756424, PMID 29886024, PMID 31253540, PMID 31679946, PMID 31697873, PMID 32546431, PMID 33023304, PMID 33095038, PMID 33581080, PMID 33734030, PMID 34437784, PMID 34942085, PMID 35190292, PMID 35771568, PMID 36921081, PMID 37154609, PMID 40209082, PMID 40454869, PMID 40788823
NIH funding
2017 (7), 2018 (6), 2019 (5), 2014 (2), 2015 (1), 2016 (1), 2023 (1)